This site uses cookies. By using this site you agree to receiving cookies. View Policy.

Successfully funded
overfunded
Rightangled
433%
Raised
£433,290
Investors
754
Target
£100,000
Equity
22.41%
Pre-money valuation
£1,500,000

Backed by NHS England, Rightangled is a CQC registered healthcare provider for genetic testing. Having designed their Cardiac genetic test and filed a patent already, the team now seek to expand their testing and telemedicine service into new tests and markets.

  • Already secured sales in the UK and USA
  • Founded by a scientist entrepreneur and an industrial designer
  • Featured in the Innovation 50
  • Working with genetic consultants from Guys & St Thomas Hospital
Information The company had £150,000 of its SEIS allowance remaining at the start of this raise. This will be allocated to investors on a first come first served basis. Any investments made after that limit has been exceeded will not be SEIS eligible but will potentially be eligible for EIS. The potential tax relief of any investment will be confirmed by email to investors, after they have submitted their applications to invest, and will depend on an investor's individual circumstances.

Idea

Rightangled is a CQC registered healthcare provider for genetic testing. Our first product “Heart DNA Test” is a cardiac genetic test for hereditary conditions, drug response and genetic predisposition to high cholesterol, triglyceride, and other nutrient levels.

Our service is inclusive of a cardiologist assessment who takes into account the patient’s self-reported medical information. Our online platform has three features:

- Medical consultations via Telemedicine

- Automated interpretation system - we convert genetic raw data into a comprehensive report (algorithms and calculations are based on a year of R&D at Birmingham Research Park and have been reviewed by genetic consultants from Guys and St Thomas Hospital in London).

- Automated assignment of patients to consultants based on an integrated barcode identification system.

Since launch in June 2017, the business has recorded sales in the UK and the US, won the Highly Commended award for its economic impact and was listed within the Innovation 50 report for most forward-thinking companies in the region (Miles and Reeve 2017).

We will be launching our next product “Fitness DNA Test” in Q2 2018; more focused on exercise responses, diet and nutrition and on cardio fitness in general. R&D for this test has already been completed.

Further DNA tests in our pipeline are for cancer, skin care and mental health medication.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

To see the rest of the Rightangled pitch, join now. It's free, quick and easy.

Due to financial regulations, you need to join our community to view the full investment opportunity.

Join

Already registered? Log in

Risk warning

Investments of this nature carry risks to your capital, including illiquidity, lack of dividends and dilution. Balance risk with a diversified portfolio. Read more. Approved as a financial promotion by Crowdcube Capital Limited, which is authorised and regulated by the Financial Conduct Authority.

Investment opportunities are not offers to the public and investors must be eligible Crowdcube members. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions. Please seek independent advice as required as Crowdcube does not give investment or tax advice.

Rightangled has been given advance assurance by HMRC that the proposed share issue is likely to qualify for Enterprise Investment Scheme (EIS) tax relief.

Tax relief is available to individuals only, with income tax relief currently set at 30 per cent of the cost of the shares for the tax year in which the investment was made. The tax reliefs can also reduce your Capital Gains Tax bill. Read More.

Availability of tax relief depends on your individual and the company’s ongoing circumstances and applicable law.